Jan 10 (Reuters) - GENSIGHT BIOLOGICS SA:
* GENSIGHT OBTAINS AUTHORIZATION OF MHRA TO START CLINICAL STUDY OF PHASE I/II PIONEER OF GENE THERAPY GS030‍​
* EXPECTS TO TREAT FIRST PATIENT IN UK IN Q1 2018‍​‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)
Our Standards: The Thomson Reuters Trust Principles.